isotretinoin
isotretinoin: sourced relationships with 1 company · 7 clinical trials tracked.
isotretinoin evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could isotretinoin → DERM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Journey Medical Corp (DERM) Severe recalcitrant nodular acne | Approved |
Clinical Trial Registry Records (7)
A Phase 2 Study of Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
Primary endpoint: Proportion of Participants who experienced acneiform rash
A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age
Primary endpoint: To determine the feasibility of adding intrathecal (IT) topotecan and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Primary endpoint: Event free survival (EFS)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Primary endpoint: Event free survival (EFS) (Arm A, B, D, and E)
Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
Primary endpoint: relapse-free survival (RFS)
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma
Primary endpoint: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Primary endpoint: Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma
Frequently asked questions
Which companies have sourced relationships with isotretinoin?
isotretinoin has dated SEC/FDA relationship records for Journey Medical Corp.
How many clinical trials involve isotretinoin?
BioSniper tracks 7 clinical trials involving isotretinoin.